Beijing SL Pharmaceutical Co Ltd (002038) — Cash Flow-to-Debt Ratio
Beijing SL Pharmaceutical Co Ltd (002038) has a Cash Flow-to-Debt Ratio of 0.20x as of September 2025, meaning its operating cash flow of CN¥66.55 Million could theoretically repay 0% of its total liabilities (CN¥327.96 Million) in one year. Explore how much of Beijing SL Pharmaceutical Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Beijing SL Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2003–2025)
Historical debt coverage capacity for Beijing SL Pharmaceutical Co Ltd across 23 annual periods. Also explore Beijing SL Pharmaceutical Co Ltd assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Beijing SL Pharmaceutical Co Ltd (2003–2025)
Year-by-year debt coverage analysis for Beijing SL Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see how much is Beijing SL Pharmaceutical Co Ltd worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.29x | CN¥257.66 Million | CN¥883.49 Million | ▼ -48.5% |
| 2024 | 0.57x | CN¥225.49 Million | CN¥398.37 Million | ▼ -42.5% |
| 2023 | 0.98x | CN¥460.20 Million | CN¥467.72 Million | ▲ +0.1% |
| 2022 | 0.98x | CN¥389.82 Million | CN¥396.60 Million | ▼ -8.1% |
| 2021 | 1.07x | CN¥464.63 Million | CN¥434.23 Million | ▲ +5.5% |
| 2020 | 1.01x | CN¥415.84 Million | CN¥410.09 Million | ▼ -38.5% |
| 2019 | 1.65x | CN¥665.83 Million | CN¥403.76 Million | ▲ +59.7% |
| 2018 | 1.03x | CN¥485.17 Million | CN¥469.73 Million | ▼ -22.5% |
| 2017 | 1.33x | CN¥380.72 Million | CN¥285.67 Million | ▼ -49.2% |
| 2016 | 2.62x | CN¥396.86 Million | CN¥151.19 Million | ▼ -22.8% |
| 2015 | 3.40x | CN¥504.87 Million | CN¥148.40 Million | ▲ +0.9% |
| 2014 | 3.37x | CN¥465.00 Million | CN¥137.92 Million | ▲ +19.5% |
| 2013 | 2.82x | CN¥347.41 Million | CN¥123.09 Million | ▼ -25.5% |
| 2012 | 3.79x | CN¥398.60 Million | CN¥105.17 Million | ▼ -16.2% |
| 2011 | 4.53x | CN¥228.59 Million | CN¥50.52 Million | ▼ -29.3% |
| 2010 | 6.40x | CN¥238.13 Million | CN¥37.22 Million | ▲ +34.8% |
| 2009 | 4.75x | CN¥174.41 Million | CN¥36.75 Million | ▼ -36.7% |
| 2008 | 7.50x | CN¥194.32 Million | CN¥25.91 Million | ▲ +194.6% |
| 2007 | 2.55x | CN¥88.36 Million | CN¥34.71 Million | ▲ +56.6% |
| 2006 | 1.63x | CN¥57.55 Million | CN¥35.41 Million | ▼ -19.8% |
| 2005 | 2.03x | CN¥47.48 Million | CN¥23.42 Million | ▲ +84.0% |
| 2004 | 1.10x | CN¥31.26 Million | CN¥28.38 Million | ▲ +32.6% |
| 2003 | 0.83x | CN¥30.55 Million | CN¥36.78 Million | — |